Patents by Inventor Anthony M. Treston

Anthony M. Treston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VALIOLAMINE DERIVATIVES AS GLUCOSIDASE INHIBITORS
    Publication number: 20240174619
    Abstract: This disclosure is directed to N-substituted valiolamine compounds, their use as glycosidase inhibitors, and in methods of treating diseases or conditions in which glycosidase inhibition provides benefit.
    Type: Application
    Filed: March 2, 2022
    Publication date: May 30, 2024
    Applicant: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
    Inventors: Anthony M. TRESTON, Kelly Lyn WARFIELD
  • STABILIZED ALKYL NITRITE COMPOSITIONS
    Publication number: 20240082198
    Abstract: This disclosure describes a composition comprising an alkyl nitrite, such as isoamyl nitrite, and an effective amount of at least one stabilizing compound, such as one or more of vitamins K1, K2, and K3.
    Type: Application
    Filed: September 30, 2021
    Publication date: March 14, 2024
    Applicant: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
    Inventors: Daniel Cope HILL, Anthony M. TRESTON
  • Methods of treating disease states using antiangiogenic agents
    Patent number: 8158612
    Abstract: Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CCCH3; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: April 17, 2012
    Assignee: EntreMed, Inc.
    Inventors: Gregory E. Agoston, Jamshed H. Shah, Lita Suwandi, Theresa M. LaVallee, Anthony M. Treston
  • Method of treating disease states using substituted pyrazole compounds
    Patent number: 8114870
    Abstract: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: February 14, 2012
    Assignee: Miikana Therapeutics, Inc.
    Inventors: Xiao-Yi Xiao, Dinish V. Patel, John S. Ward, Mark R. Bray, Gregory E. Agoston, Anthony M. Treston
  • METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS
    Publication number: 20090264422
    Abstract: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
    Type: Application
    Filed: June 30, 2009
    Publication date: October 22, 2009
    Inventors: Xiao-Yi Xiao, Dinish V. Patel, John S. Ward, Mark R. Bray, Gregory E. Agoston, Anthony M. Treston
  • Substituted pyrazole compounds
    Patent number: 7563787
    Abstract: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: July 21, 2009
    Assignee: Miikana Therapeutics, Inc.
    Inventors: Xiao-Yi Xiao, Dinish V. Patel, John S. Ward, Mark R. Bray, Gregory E. Agoston, Anthony M. Treston
  • METHODS OF TREATING DISEASE STATES USING ANTIANGIOGENIC AGENTS
    Publication number: 20090105205
    Abstract: Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CCCH3; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.
    Type: Application
    Filed: December 22, 2008
    Publication date: April 23, 2009
    Applicant: ENTREMED, INC.
    Inventors: Gregory E. Agoston, Jamshed H. Shah, Lita Suwandi, Theresa M. LaVallee, Anthony M. Treston
  • Antiangiogenic agents
    Patent number: 7498322
    Abstract: Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CCCH3; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: March 3, 2009
    Assignee: EntreMed, Inc.
    Inventors: Gregory E. Agoston, Jamshed H. Shah, Lita Suwandi, Theresa M. LaVallee, Anthony M. Treston
  • SUBSTITUTED PYRAZOLE COMPOUNDS
    Publication number: 20090029992
    Abstract: Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
    Type: Application
    Filed: June 11, 2008
    Publication date: January 29, 2009
    Inventors: GREGORY E. AGOSTON, Anthony M. Treston, Gaetan Ladouceur, Lita Suwandi
  • METHOD OF TREATING AMYLOIDOSIS MEDIATED DISEASES
    Publication number: 20080234243
    Abstract: The compounds of the present invention can be used to inhibit formation of beta-amyloid protein. The present invention provides methods of preventing, delaying onset of, or treating diseases or conditions characterized or mediated by amyloidosis. In particular, the present invention is useful for preventing, delaying onset of, and treating Alzheimer's disease and related diseases causing dementia.
    Type: Application
    Filed: January 31, 2008
    Publication date: September 25, 2008
    Inventors: Theresa M. LaVallee, Anthony M. Treston, Todd A. Hembrough
  • Estradiol derivatives and pharmaceutical compositions using same
    Patent number: 7371741
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: May 13, 2008
    Assignee: EntreMed, Inc.
    Inventors: Gregory E. Agoston, Theresa M. LaVallee, Victor S. Pribluda, Jamshed H. Shah, Anthony M. Treston
  • Methods of using 2-methoxyestradiol of high purity
    Patent number: 7235540
    Abstract: 2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purification methods of the invention involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds. The chromatographic media is preferably silica. The solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: June 26, 2007
    Assignee: EntreMed, Inc.
    Inventors: Gregory E. Agoston, Jamshed H. Shah, Anthony M. Treston
  • Antiangiogenic agents
    Patent number: 7135581
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: November 14, 2006
    Assignee: Entremed, Inc.
    Inventors: Gregory E. Agoston, Jamshed H. Shah, Kimberly A. Hunsucker, Victor S. Pribluda, Theresa M. LaVallee, Shawn J. Green, Christopher J. Herbstritt, Xiaoguo H. Zhan, Anthony M. Treston
  • Compositions comprising purified 2-methoxyestradiol and methods of producing same
    Patent number: 7087592
    Abstract: 2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purification methods of the invention involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds. The chromatographic media is preferably silica. The solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: August 8, 2006
    Assignee: Entre Med, Inc.
    Inventors: Gregory E. Agoston, Jamshed H. Shah, Anthony M. Treston
  • Antiangiogenic agents
    Patent number: 6995278
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: February 7, 2006
    Assignee: Entre Med, Inc.
    Inventors: Gregory E. Agoston, Victor Pribluda, Anthony M. Treston, Shawn J. Green
  • Methods of obtaining 2-methoxyestradiol of high purity
    Publication number: 20040097479
    Abstract: 2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purification methods of the invention involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds. The chromatographic media is preferably silica. The solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.
    Type: Application
    Filed: July 1, 2003
    Publication date: May 20, 2004
    Inventors: Gregory E. Agoston, Jamshed H. Shah, Anthony M. Treston
  • Non-steroidal analogs of 2-methoxyestradiol
    Publication number: 20030236439
    Abstract: Compounds, compositions, and methods for treating disease states characterized by undesirable angiogenesis, proliferative activity, or cell mitosis by administering non-steroidal analogs of 2-methoxyestradiol of the general formula: 1
    Type: Application
    Filed: January 30, 2003
    Publication date: December 25, 2003
    Inventors: Gregory Agoston, Jamshed H. Shah, Kimberly A. Hunsucker, Anthony M. Treston, Victor S. Pribluda
  • Non-steroidal analogs of 2-methoxyestradiol
    Publication number: 20030187076
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis and proliferative activity by administering non-steroidal derivatives of 2-methoxyestradiol of the general formula: 1
    Type: Application
    Filed: January 30, 2003
    Publication date: October 2, 2003
    Inventors: Gregory E. Agoston, Jamshed H. Shah, Kimberly A. Hunsucker, Anthony M. Treston, Victor S. Pribluda
  • Antiangiogenic agents
    Publication number: 20020147183
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: 1
    Type: Application
    Filed: February 8, 2001
    Publication date: October 10, 2002
    Inventors: Gregory E. Agoston, Victor Pribluda, Anthony M. Treston, Shawn J. Green
  • Antiangiogenic agents
    Publication number: 20020082433
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: 1
    Type: Application
    Filed: August 24, 2001
    Publication date: June 27, 2002
    Inventors: Gregory E. Agoston, Jamshed H. Shah, Kimberly A. Hunsucker, Victor S. Pribluda, Theresa M. LaVallee, Shawn J. Green, Christopher J. Herbstritt, Xiaoguo H. Zhan, Anthony M. Treston